Functional CCR5 receptor protects patients with arthritis from high synovial burden of infecting Chlamydia trachomatis.
BACKGROUND
The CCR5 chemokine receptor occurs in a wild-type (wt) and a nonfunctional deleted form (Δ32). Reports suggested that Chlamydia-induced reproductive tract pathology is attenuated in women bearing Δ32. The authors asked whether the mutation affects synovial prevalence and burden of Chlamydia trachomatis.


METHODS
Polymerase chain reaction (PCR) defined CCR5 genotype in synovial tissue DNA from 218 individuals: 21 controls, 110 with reactive arthritis (ReA), 83 with undifferentiated oligoarthritis (UO), 4 with osteoarthritis (OA). Disease durations were 0.5 to 21 years. Additional PCR assays defined the presence of C trachomatis DNA. Bacterial load was assessed by real-time PCR in selected samples.


RESULTS
Five controls were wt/Δ32, 16 were wt/wt; 2 of 21 controls (both wt/wt) were PCR positive for C trachomatis. Eighty-five (44%) patients with arthritis were PCR positive for C trachomatis (69 ReA and 16 UO). For patients with ReA, 14 (13%) had wt/Δ32, 10 (71%) of whom were PCR positive. Nineteen patients with UO (23%) were wt/Δ32, with 1 (1%) PCR positive. No differences existed for gender or other factors. One patient with OA had wt/Δ32. In ReA and UO samples, wt/Δ32 heterozygotes had a 5- to 10-fold higher bacterial burden than did wt/wt patients (P = 0.03), regardless of diagnosis.


CONCLUSIONS
These results indicate that the wt/wt genotype is associated with attenuated synovial bacterial load compared with loads in wt/Δ32 patients. Although no alleles other than Δ32 were assessed, our data suggest that this allele provides little/no protection from ReA in patients infected with Chlamydia- but it may provide some protection in patients with UO. The basis of this possible differential effect of CCR5 genotype is under study.
Gérard
Hervé C
HC
Department of Immunology and Microbiology, Wayne State University School of Medicine, Detroit, Michigan 48201, USA.
Stanich
Jessica A
JA
Oszust
Cynthia E
CE
Whittum-Hudson
Judith A
JA
Carter
John D
JD
Schumacher
H Ralph
HR
Hudson
Alan P
AP
D001168:Arthritis / Q000276:immunology*; D016918:Arthritis, Reactive / Q000517:prevention & control*; D002690:Chlamydia Infections / Q000276:immunology*; D002692:Chlamydia trachomatis; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D000091402:Prohibitins; D019713:Receptors, CCR5 / Q000235:genetics / Q000502:physiology*; D013583:Synovial Membrane / Q000382:microbiology*
C000717331:PHB2 protein, human; D000091402:Prohibitins; D019713:Receptors, CCR5
Microb Pathog. 2005 Jul-Aug;39(1-2):19-26
15998578
Arthritis Rheum. 2009 May;60(5):1311-6
19404948
Autoimmunity. 2009 May;42(4):260-2
19811270
Arthritis Res Ther. 2009;11(3):R91
19538721
J Rheumatol. 1998 Apr;25(4):734-42
9558178
Nat Genet. 1997 Jul;16(3):221-2
9207783
J Immunol. 2005 Jun 1;174(11):7186-93
15905563
Clin Exp Rheumatol. 2008 Jan-Feb;26(1 Suppl 48):S27-32
18570751
QJM. 2006 Aug;99(8):497-503
16880184
J Microbiol Immunol Infect. 2005 Aug;38(4):244-54
16118671
Clin Exp Rheumatol. 2008 Jan-Feb;26(1 Suppl 48):S12-7
18570749
Ann Rheum Dis. 2005 Mar;64(3):487-90
15331395
J Exp Med. 2006 Jan 23;203(1):35-40
16418398
J Rheumatol. 1994 Jan;21(1):115-22
8151565
Nature. 1996 Aug 22;382(6593):722-5
8751444
Scand J Rheumatol. 2008 Jan-Feb;37(1):13-7
18189189